IDEV Technologies initiated the first procedures in Europe utilising the new 6 French (6Fr) Supera Veritas peripheral vascular system. The new lower profile delivery system offers physicians more treatment options, easier operation, and greater delivery control, while providing the unique strength, flexibility, and performance benefits of the Supera stent.
The 6Fr size allows a smaller access site and multiple approach options when treating patients with peripheral artery disease, which can be particularly important when treating stenoses or occlusions in the superficial femoral artery and the popliteal artery. In addition to having a lower entry profile, the new 6Fr system is available in two catheter lengths, 80cm and 120cm, and offers even better efficiency and trackability.
Initial procedures were done last month at Canisius-Wilhelmina Ziekenhuis (CWZ) in Nijmegen, The Netherlands and also at three German sites: Park Hospital in Leipzig, Heart Centre Bad Krozingen, and University Hospital in Heidelberg.
“The new 6Fr system allowed for better control of stent deployment while requiring less force to deliver,” commented Andrej Schmidt, Park Hospital, Leipzig, Germany. “In addition, the modified outer sheath easily tracked through tortuous anatomy. Over the years, IDEV has continued to refine the stent delivery system to provide greater utility and flexibility to physicians.”
Sebastian Sixt, Herz Zentrum (Heart Centre) Bad Krozingen, Germany, commented: “I appreciate how easily I can control the stent delivery. The improved delivery makes it very straightforward to predict the stent landing zone, and treat the lesion appropriately.”
“Many of our procedures utilise 6Fr systems, so having Supera Veritas now available in this size allows us to use our stent of choice without switching to a different sheath.” Peter Haarbrink, CWZ, The Netherlands, said.
A full launch of the lower profile 6Fr Supera Veritas peripheral vascular system will occur this summer throughout Europe.
The Supera stent is currently indicated in the United States for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe, Canada and Australia for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty.
